• Record 4,100+ registered mums on HeraCARE platform
• 389 mothers onboarded at Broward Health, 9 care plans live
• $4.1M raised to support commercial deployments and integrations

HeraMED Limited (ASX:HMD), a medical data and technology company leading the digital transformation of maternity care, has provided its Appendix 4C cashflow statement and review of operations for the December 2024 quarter (Q4 FY24). Key highlights include: record 4,103 accumulated registered mums on the HeraCARE platform as of 27 January 2025, including 554 active users; 389 mothers now onboarded to HeraCARE at Broward Health since platform go-live, with 9 care plans now live; $4.1 million raised in new capital during the quarter to support commercial deployments, pilots and integration of HeraCARE; LOI executed with Metronomic Inc to develop leading postpartum care solution for the US market; and key advisory board appointments made with Vivek Krishnan and Cheryle Royle. The company continues to make strong progress in advancing its 4-point strategic plan, with a focus on deep collaboration with key customers, strategic partnerships, non-dilutive funding, and strengthening its advisory team.

The company did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.

Looking ahead to 2025 and beyond, the CEO is more optimistic than ever about HeraCARE's opportunity and capability to transform the standard in prenatal and postpartum care, revolutionising outcomes for mothers and babies worldwide.